Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
10.90
-0.20 (-1.80%)
Jan 21, 2026, 11:20 AM CET
25.43%
Market Cap3.12B
Revenue (ttm)8.50M
Net Income (ttm)-424.45M
Shares Out281.53M
EPS (ttm)-1.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume146,924
Average Volume890,710
Open11.06
Previous Close11.10
Day's Range10.86 - 11.08
52-Week Range6.09 - 14.10
Beta0.21
RSI48.46
Earnings DateFeb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.